Broad-acting antihistamine has potential in number of disease areas with unmet clinical need NEW YORK and LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Akari …
Press Release
Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering
NEW YORK and LONDON, March 8, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative …
[Read more...] about Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of …
Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma
Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program …
Akari Therapeutics to Present at BIO CEO & Investor Conference
NEW YORK and LONDON, February 11, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics to Present at BIO CEO & Investor Conference
